This joint guidance by the ECDC and EMCDDA aims to strengthen the evidence base for developing national strategies for preventing and controlling infections and infectious diseases among people who inject drugs.
In 2022, 30 EU/EEA countries reported 4 149 confirmed cases of shigellosis. Of those cases with information available on travel history, 48% were associated with travel.
ECDC’s annual surveillance reports provide a wealth of epidemiological data to support decision-making at the national level. They are mainly intended for public health professionals and policymakers involved in disease prevention and control programmes.
The food-borne infections listeriosis and shigatoxigenic Escherichia coli are increasing in the EU/EEA and were in 2022 at levels higher than before the COVID-19 pandemic.
In 2022, 30 EU/EEA countries reported 4 548 cases of hepatitis A. The EU/EEA notification rate was one case per 100 000 population. Twenty EU/EEA countries had notification rates below one case per 100 000 population. The countries with the highest notification rates were Hungary (5.5), Croatia (5.3) Romania (4.8), and Bulgaria (4.4).
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 21-27 January 2024 and includes updates on SARS-CoV-2, influenza, cholera, chikungunya, dengue and zika.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 17-23 December 2023 and includes updates on cholera, SARS-CoV-2 variant classification, avian influenza in fur farms, hepatitis A, pertussis, a cluster of extensively drug-resistant Shigella Sonnei among men who have sex with men, and an overview of respiratory virus epidemiology in the EU/EE.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 19 - 25 November 2023 and includes updates on updates SARS-CoV-2 variant classifications, the increase of pediatric respiratory infections in China, Avian influenza in fur farms, West Nile virus, cholera, and an overview of respiratory virus epidemiology.
A joint study of the National Public Health Organization in Greece (NPHO) and the European Centre for Disease Prevention and Control (ECDC) conducted in 15 Greek hospitals in 2022 sheds light on the rapid spread of carbapenemase-producing, highly drug-resistant Klebsiella pneumoniae sequence type (ST) 39, following its initial documentation in a European-wide genomic survey in 2019.